Profile data is unavailable for this security.
About the company
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases. Its specialty medicines prevent and treat diseases, from human immunodeficiency virus (HIV) to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from a range of diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD, antibiotics and medicines for skin diseases. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
- Revenue in USD (TTM)42.30bn
- Net income in USD4.23bn
- Incorporated1999
- Employees68.63k
- LocationGSK plc980 Great West RoadBRENTFORD TW8 9GSUnited KingdomGBR
- Phone+44 208 047 5000
- Fax+44 208 047 7807
- Websitehttps://www.gsk.com/
Mergers & acquisitions
| Acquired company | GSK:LSE since announced | Transaction value |
|---|---|---|
| CELLphenomics GmbH | 1.54% | -- |
| IDRx Inc | -0.11% | 1.15bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biogen Inc | 9.82bn | 1.48bn | 18.86bn | 7.61k | 12.71 | 1.11 | 8.54 | 1.92 | 10.13 | 10.13 | 67.18 | 115.90 | 0.3596 | 1.00 | 4.91 | 1,290,782.00 | 5.42 | 9.02 | 6.42 | 10.69 | 75.58 | 81.00 | 15.07 | 21.25 | 1.01 | 4.81 | 0.2706 | 0.00 | -1.62 | -7.62 | 40.57 | -22.63 | -11.68 | -- |
| Royalty Pharma plc | 2.26bn | 1.09bn | 19.94bn | 99.00 | 14.47 | 3.00 | 59.65 | 8.81 | 2.45 | 2.45 | 3.84 | 11.81 | 0.1342 | -- | 98.40 | 22,867,120.00 | 10.48 | 7.56 | 13.62 | 10.21 | -- | -- | 78.12 | 55.06 | -- | 14.51 | 0.4376 | 46.51 | -3.86 | 4.52 | -24.31 | -18.22 | 7.80 | -- |
| Alnylam Pharmaceuticals, Inc. | 2.35bn | -269.70m | 42.34bn | 2.23k | -- | 366.53 | -- | 18.03 | -2.09 | -2.09 | 18.27 | 0.8858 | 0.5842 | 4.12 | 9.70 | 1,052,959.00 | -6.71 | -20.07 | -8.96 | -25.51 | 86.01 | 84.18 | -11.49 | -55.19 | 2.98 | -0.4627 | 0.8988 | -- | 22.97 | 59.21 | 36.82 | -- | -24.55 | -- |
| Regeneron Pharmaceuticals Inc | 14.09bn | 4.50bn | 59.38bn | 15.11k | 14.00 | 2.03 | 11.89 | 4.22 | 39.30 | 39.30 | 123.45 | 271.60 | 0.3917 | 0.6347 | 2.61 | 932,457.30 | 12.51 | 18.52 | 13.89 | 21.13 | 86.69 | 87.22 | 31.94 | 37.92 | 4.03 | -- | 0.0843 | -- | 8.27 | 12.55 | 11.61 | 15.84 | 15.46 | -- |
| Zoetis Inc | 9.29bn | 2.52bn | 66.79bn | 13.80k | 26.94 | 14.38 | 22.13 | 7.19 | 5.57 | 5.57 | 20.54 | 10.44 | 0.6529 | 1.07 | 7.00 | 672,898.60 | 17.77 | 15.25 | 21.83 | 18.31 | 70.98 | 70.18 | 27.22 | 26.32 | 1.04 | 21.14 | 0.5856 | 28.93 | 8.33 | 8.14 | 6.06 | 10.63 | 7.32 | 21.37 |
| GSK plc (ADR) | 42.30bn | 4.23bn | 77.44bn | 68.63k | 17.83 | 3.98 | 8.40 | 1.83 | 2.05 | 2.05 | 20.51 | 9.16 | 0.5289 | 1.51 | 4.54 | 616,304.90 | 6.11 | 6.26 | 9.14 | 9.86 | 72.01 | 70.75 | 11.55 | 15.56 | 0.5801 | 15.02 | 0.5745 | 80.46 | 3.46 | -1.45 | -47.75 | -11.13 | 6.63 | -- |
| Bristol-Myers Squibb Co | 47.64bn | 5.42bn | 97.81bn | 34.10k | 18.04 | 5.62 | 7.24 | 2.05 | 2.66 | 2.66 | 23.44 | 8.54 | 0.4976 | 4.27 | 5.12 | 1,396,950.00 | 5.68 | 0.6536 | 7.69 | 0.8175 | 74.69 | 76.63 | 11.41 | 1.52 | 1.17 | 7.39 | 0.7402 | 678.24 | 7.32 | 13.06 | -211.50 | -- | 8.34 | 7.91 |
| Holder | Shares | % Held |
|---|---|---|
| Dodge & Coxas of 31 Mar 2025 | 78.65m | 3.80% |
| Fisher Asset Management LLCas of 31 Mar 2025 | 30.03m | 1.45% |
| Strategic Advisers LLCas of 31 Mar 2025 | 27.29m | 1.32% |
| PRIMECAP Management Co.as of 31 Mar 2025 | 25.71m | 1.24% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2025 | 23.32m | 1.13% |
| JTC Plc /Private Banking/as of 31 Mar 2025 | 15.26m | 0.74% |
| FIAM LLCas of 31 Mar 2025 | 9.52m | 0.46% |
| Goldman Sachs Asset Management LPas of 31 Mar 2025 | 8.47m | 0.41% |
| T. Rowe Price International Ltd.as of 31 Mar 2025 | 7.72m | 0.37% |
| UBS Securities LLCas of 31 Mar 2025 | 7.49m | 0.36% |
